Table 1. Patient Characteristics.

	No. (%)
	(N = 136)
Sex
Male	79 (58)
Female	57 (42)
WHO performance status
0	77 (57)
≥1	59 (43)
Prior nephrectomy	135 (99)
Reason for stopping sunitinib
Progression	81 (60)
Adverse events/other	55 (40)
Heng risk group
Favourable	67 (49)
Intermediate	30 (22)
Poor	35 (26)
N.A.	4 (3)
MSKCC risk group
Favourable	22 (16)
Intermediate	81 (60)
Poor	22 (16)
N.A.	11 (8)
Histological type
Clear cell	120 (88)
Papillary	12 (9)
Other	4 (3)

Abbreviations: WHO, World Health Organization; N.A, not available; MSKCC, Memorial Sloan-Kettering Cancer Center